• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

ritchied@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
Department of Medicine
ORCID

0000-0001-7329-6605

Prof David Ritchie

Honorary (Professorial Fellow)
Department of Medicine

520 Scholarly works
13 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
    DOI: 10.1016/S2352-3026(26)00005-0
  • 2026

    Journal article

    Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
    DOI: 10.1182/bloodadvances.2025016646
  • 2026

    Journal article

    T cell and monocyte activation in concert with hematopoietic stem cell interactions shapes the post-allogeneic transplant immune landscape in poor graft function
    DOI: 10.3389/fimmu.2026.1750093
  • 2026

    Journal article

    Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas
    DOI: 10.1080/10428194.2025.2579721
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Diagnosis, Discovery and Novel Phenotype Characterisation Using Multimodal Genomics in Patients With Inherited Bone Marrow Failure and Related Disorders
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Repurposing BCL-2 Inhibitors for Immune Manipulation to Improve Outcomes in Allogeneic Stem Cell Transplantation
  • 2018

    Research Grant

    Inhibiting BCL-2 and Nk Cells Improves Stem Cell Transplant Outcomes in Acute Myeloid Leukaemia
David Ritchie

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia
    DOI: 10.1080/10428194.2025.2599991
  • 2026

    Journal article

    KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia
    DOI: 10.1080/10428194.2026.2615055
  • 2025

    Other

    Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
    DOI: 10.1158/1078-0432.30707564
  • 2025

    Journal article

    Establishing the impact of effective donor-specific antibody (DSA) desensitisation in haploidentical and mismatched donor haematopoietic stem cell transplants: An Australian experience
    DOI: 10.1182/blood-2025-4199
  • 2025

    Journal article

    Utilisation of machine learning algorithms to predict relapse risk following allogeneic stem cell transplantation (alloSCT) for patients with myeloid malignancies
    DOI: 10.1182/blood-2025-6081
  • 2025

    Journal article

    Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study
    DOI: 10.1182/blood-2025-3341

RECENT PROJECTS

  • 2026

    Research contracts (non-grants)

    Developing Translational Insights Into Poor Graft Function Following Allogeneic Stem Cell Transplantation
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Personalised Haematopoietic Stem Cells, Moving Transplantation Into the 21st Century

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224